The Saara Laukkanen team uncovered potent drug synergies between AKT/mTORC1 inhibitors and the general tyrosine kinase inhibitor dasatinib, and this combination effectively curbed T‐cell acute lymphoblastic leukemia (T‐ALL) growth in primary human T‐ALL.26 This evidence concerns the gene AKT1 and acute lymphoblastic leukemia.